Get the Stockscreener App
7.07
2.46%
0.17
After Hours:
7.06
-0.01
-0.14%
Engene Holdings Inc stock is traded at $7.07, with a volume of 114.31K.
It is up +2.46% in the last 24 hours and down -30.00% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$6.90
Open:
$6.94
24h Volume:
114.31K
Relative Volume:
0.28
Market Cap:
$473.62M
Revenue:
-
Net Income/Loss:
$-122.44M
P/E Ratio:
-3.1366
EPS:
-2.254
Net Cash Flow:
$-103.79M
1W Performance:
-1.53%
1M Performance:
-30.00%
6M Performance:
+8.77%
1Y Performance:
+43.41%
1-Day Range:
$6.94
$7.30
1-Week Range:
$6.71
$7.50
52-Week Range:
$2.65
$12.25
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
7.07 | 462.23M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Jefferies | Buy |
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trapPortfolio Update Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
AI Stocks: What analysts say about enGene Holdings Inc Equity Warrant stockMarket Activity Report & Verified Chart Pattern Signals - baoquankhu1.vn
UBS cuts Engene Holdings stock price target on trial costs - Investing.com UK
Volume Recap: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc a stock for growth or value investors2026 Short Interest & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Sell Signal: How does enGene Holdings Inc compare to its peersQuarterly Risk Review & Verified Momentum Stock Alerts - baoquankhu1.vn
Valuation Update: What analysts say about enGene Holdings Inc Equity Warrant stock2026 Snapshot & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bank Watch: Is enGene Holdings Inc Equity Warrants ROE strong enough2026 Sector Review & Verified Momentum Stock Alerts - baoquankhu1.vn
ENGN PE Ratio & Valuation, Is ENGN Overvalued - Intellectia AI
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care - The Globe and Mail
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - MarketBeat
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - MarketBeat
Portfolio Update: Is enGene Holdings Inc stock a good dividend stock2026 Performance Recap & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aug Reactions: Why is enGene Holdings Inc Equity Warrant stock going up2026 EndofYear Setup & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7% - MarketBeat
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - MarketBeat
Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN - MarketBeat
enGene (NASDAQ:ENGN) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Oppenheimer Issues Pessimistic Forecast for enGene (NASDAQ:ENGN) Stock Price - Defense World
Merger Talk: Can enGene Holdings Inc Equity Warrant lead its sector in growth2026 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
AI Stocks: Will enGene Holdings Inc stock benefit from M A2026 Short Interest & Entry and Exit Point Strategies - baoquankhu1.vn
enGene Holdings: Key Catalysts Incoming For 2026 (NASDAQ:ENGN) - Seeking Alpha
enGene (NASDAQ:ENGN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline By Investing.com - Investing.com South Africa
HC Wainwright Has Optimistic Outlook of enGene Q2 Earnings - MarketBeat
Citizens reiterates Engene Holdings stock rating on BLA timeline - Investing.com
FY2030 Earnings Forecast for enGene Issued By HC Wainwright - Defense World
enGene Shares Gain 5% After Bladder Cancer Therapy Shows Stronger Response Rates - MSN
enGene (NASDAQ:ENGN) Price Target Lowered to $30.00 at Oppenheimer - MarketBeat
Pullback Watch: How does enGene Holdings Inc compare to its peers2026 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
ENGN: Detalimogene offers promising efficacy and convenience for NMIBC, with pivotal data updates ahead - TradingView
HC Wainwright Has Positive Outlook of enGene FY2030 Earnings - MarketBeat
enGene Holdings (ENGN) Gets a Buy from Wells Fargo - The Globe and Mail
Smart Money: Can SIFCO Industries Inc continue delivering strong returns2026 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
ENGN: Detalimogene's pivotal data and unique profile position it to transform NMIBC treatment - TradingView
enGene (NASDAQ:ENGN) Posts Earnings Results, Beats Estimates By $0.11 EPS - MarketBeat
ENGN: Detalimogene offers a unique, highly tolerable NMIBC therapy with pivotal data updates in 2024 - TradingView
Engene stock price target lowered to $27 by Guggenheim on estimates By Investing.com - Investing.com India
Engene stock price target lowered to $27 by Guggenheim on estimates - Investing.com Australia
enGene Holdings Inc. Announces Sales Agreement with Leerink Partners LLC for At-the-Market Offering of Common Shares - Minichart
Raymond James Maintains Strong Buy on ENGN enGene Holdings Inc March 2026 - Meyka
enGene Holdings Inc. Q1 2026 Quarterly Report: Financial Statements, Management Discussion & Key Disclosures - Minichart
enGene Reports Q1 2026 Results, Advances Detalimogene for Bladder Cancer with Strong Cash Position and FDA Milestones 12 - Minichart
enGene (NASDAQ:ENGN) Shares Gap DownHere's Why - MarketBeat
Raymond James reiterates Engene Holdings stock Strong Buy rating By Investing.com - Investing.com South Africa
ENGN: Detalimogene achieves 62% 6-month CR rate in NMIBC with strong safety and operational advantages - TradingView
HC Wainwright Reiterates 'Buy' Rating for enGene Holdings (ENGN) - GuruFocus
enGene's (ENGN) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
EnGene Holdings Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 - marketscreener.com
Raymond James reiterates Engene Holdings stock Strong Buy rating - Investing.com
enGene Reports First Quarter 2026 Financial Results and Provides Business Update - BioSpace
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):